NIM
LAB icon

Needham Investment Management’s Standard BioTools LAB Stock Holding History

Needham Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.7K Sell
34,435
-175,000
-84% -$212K ﹤0.01% 176
2025
Q4 		$268K Sell
209,435
-225,000
-52% -$302K 0.02% 160
2025
Q3 		$565K Hold
434,435
– – 0.04% 145
2025
Q2 		$521K Sell
434,435
-100,000
-19% -$111K 0.04% 141
2025
Q1 		$577K Sell
534,435
-200,000
-27% -$281K 0.05% 138
2024
Q4 		$1.29M Sell
734,435
-50,000
-6% -$93.1K 0.1% 124
2024
Q3 		$1.51M Sell
784,435
-200,000
-20% -$392K 0.12% 116
2024
Q2 		$1.74M Sell
984,435
-140,000
-12% -$342K 0.14% 113
2024
Q1 		$3.05M Hold
1,124,435
– – 0.28% 85
2023
Q4 		$2.49M Sell
1,124,435
-100,000
-8% -$213K 0.31% 79
2023
Q3 		$3.55M Sell
1,224,435
-810,000
-40% -$2.12M 0.6% 50
2023
Q2 		$3.93M Sell
2,034,435
-835,565
-29% -$1.65M 0.65% 47
2023
Q1 		$5.6M Sell
2,870,000
-927,157
-24% -$1.83M 0.97% 34
2022
Q4 		$4.44M Sell
3,797,157
-65,000
-2% -$80K 0.8% 42
2022
Q3 		$4.25M Sell
3,862,157
-11,746
-0.3% -$17.8K 0.83% 40
2022
Q2 		$6.2M Buy
3,873,903
+95,565
+3% +$236K 1.16% 32
2022
Q1 		$13.6M Buy
3,778,338
+263,338
+7% +$910K 1.96% 16
2021
Q4 		$13.8M Buy
3,515,000
+225,000
+7% +$1.05M 1.73% 18
2021
Q3 		$21.7M Buy
3,290,000
+39,750
+1% +$262K 2.89% 8
2021
Q2 		$20M Buy
3,250,250
+847,750
+35% +$4.53M 2.93% 8
2021
Q1 		$10.9M Buy
2,402,500
+1,152,500
+92% +$6.33M 1.48% 23
2020
Q4 		$7.5M Buy
1,250,000
+470,000
+60% +$3.09M 1.26% 29
2020
Q3 		$5.79M Buy
780,000
+217,500
+39% +$1.5M 1.16% 32
2020
Q2 		$2.26M Buy
+562,500
New +$1.96M 0.48% 58

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Needham Investment Management's LAB Position: Q1 2026 in Review

Needham Investment Management reduced its Standard BioTools (LAB) stake by 84% in Q1 2026, selling an estimated $212K and leaving 34,435 shares worth $31.7K. The position accounts for ﹤0.01% of the portfolio, ranked #176.

Needham Investment Management first reported a position in LAB in Q2 2020 and has held it in 24 quarters since. The position peaked at $21.7M in Q3 2021. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Needham Investment Management held 34,435 shares of Standard BioTools worth $31.7K as of Q1 2026.
  • Needham Investment Management sold 175,000 Standard BioTools shares in Q1 2026, an estimated $212K.
  • Standard BioTools made up ﹤0.01% of Needham Investment Management's portfolio in Q1 2026, its #176 holding.
  • Needham Investment Management first reported a position in Standard BioTools in Q2 2020 and has held it in 24 quarters since.
  • Needham Investment Management's Standard BioTools position peaked at $21.7M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Needham Investment Management's 13F filing for Q1 2026, filed 15 May 2026.